Company: SUPN
Filing Date: 2025-05-06
Form Type: 10-Q
Source: 0001356576-25-000033
Chunk: 88

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-05-06
Form: 10-Q
Item: Part I, Item 8
Chunk 88
---
 one reportable segment. The Company derives revenue primarily from sales of its commercial products in the U.S.The Company's chief operating decision maker (CODM) is the chief executive officer. The Company manages the business activities on a consolidated basis. The CODM assesses performance of the Company, decides how to allocate resources based on net income (loss), which is reported in the condensed consolidated statement of earnings (loss) as net earnings (loss), and allocates resources on a consolidated basis. The CODM uses net earnings (loss) to decide whether to reinvest profits into the Company's current products or into other research and development initiatives for the Company's product candidates. Net earnings is also used to monitor budget versus actual results.The measure of the reportable segment assets is reported on the balance sheet as total assets. 

17

The following table shows the segment revenue, significant segment expenses and net earnings (dollars in thousands):March 31,2025March 31,2024(unaudited)(unaudited)Total revenues$149,824 $143,644 Less: Significant segment expenses:Cost of goods sold15,763 16,309 Selling42,614 39,014 Marketing20,664 20,553 General and administrative26,666 26,949 Research and development expensesExternal development program expenses:ONAPGO472 784 SPN-8204,763 6,738 SPN-8173,571 1,122 Qelbree4,413 2,051 Early-stage programs and other expenses3,213 4,015 Total external development program expenses16,432 14,710 Internal employee-related expenses10,495 10,220 Total research and development expenses26,927 24,930 Other segment items(a)29,017 15,765 Net earnings (loss)$(11,827)$124 (a) Other segment items include amortization of intangible assets, intangible asset impairment charges, contingent consideration gain or loss, net interest and other income, interest expense, and income tax expense, whose amounts are disclosed in the condensed consolidated statement of earnings (loss).

14.    Composition of Other Balance Sheet Items

The following details the composition of other balance sheet items (dollars in thousands for amounts in tables):

Inventories, Net March 31,2025December 31,2024(unaudited)Raw materials$8,664 $11,127